《体外膜肺氧合中混合气体限制氧含量：一项随机对照注册研究（BLENDER）试验：研究方案和统计分析计划》勘误 [《危重病急救复苏》25 (2023) 118 - 125]
Corrigendum to "Blend to Limit OxygEN in ECMO: A RanDomised ControllEd Registry (BLENDER) trial: Study protocol and statistical analysis plan" [Crit Care Resuscit 25 (2023) 118-125].
作者信息
Burrell Aidan, Ng Sze, Ottosen Kelly, Bailey Michael, Buscher Hergen, Fraser John, Udy Andrew, Gattas David, Totaro Richard, Bellomo Rinaldo, Forrest Paul, Martin Emma, Reid Liadain, Ziegenfuss Marc, Eastwood Glenn, Higgins Alisa, Hodgson Carol, Litton Edward, Nair Priya, Orford Neil, Pellegrino Vince, Shekar Kiran, Trapani Tony, Pilcher David
机构信息
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, VIC, Australia.
出版信息
Crit Care Resusc. 2024 Feb 1;26(1):60. doi: 10.1016/j.ccrj.2024.01.003. eCollection 2024 Mar.
Abstract
[This corrects the article DOI: 10.1016/j.ccrj.2023.06.001.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.ccrj.2023.06.001。]
相似文献
1
Corrigendum to "Blend to Limit OxygEN in ECMO: A RanDomised ControllEd Registry (BLENDER) trial: Study protocol and statistical analysis plan" [Crit Care Resuscit 25 (2023) 118-125].《体外膜肺氧合中混合气体限制氧含量：一项随机对照注册研究（BLENDER）试验：研究方案和统计分析计划》勘误 [《危重病急救复苏》25 (2023) 118 - 125]
Crit Care Resusc. 2024 Feb 1;26(1):60. doi: 10.1016/j.ccrj.2024.01.003. eCollection 2024 Mar.
2
Blend to Limit OxygEN in ECMO: A RanDomised ControllEd Registry (BLENDER) Trial: Study Protocol and Statistical Analysis Plan.体外膜肺氧合中限制氧合的混合治疗：一项随机对照注册研究（BLENDER）试验：研究方案和统计分析计划
Crit Care Resusc. 2023 Aug 4;25(3):118-125. doi: 10.1016/j.ccrj.2023.06.001. eCollection 2023 Sep.
3
Corrigendum to "Statistical analysis plan for the biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2) study: An international randomised controlled multicentre trial" Crit Care Resusc. 26(2) (2024) 80-86. eCollection 2024 Jun.《生物标志物引导干预预防大手术后急性肾损伤（BigpAK - 2）研究的统计分析计划：一项国际随机对照多中心试验》勘误 危重病急救复苏杂志。2024年第26卷第2期，第80 - 86页。2024年6月电子期刊。
Crit Care Resusc. 2024 Sep 12;26(3):223. doi: 10.1016/j.ccrj.2024.09.001. eCollection 2024 Sep.
4
Corrigendum to "Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis" [Crit Care Resusc 23(3) (2021) 273-284].《BLING III研究的统计分析计划勘误：一项关于脓毒症重症患者连续与间歇β-内酰胺类抗生素输注的3期多中心随机对照试验》[《重症监护与复苏》23(3) (2021) 273 - 284]
Crit Care Resusc. 2023 May 20;25(1):60. doi: 10.1016/j.ccrj.2023.04.012. eCollection 2023 Mar.
5
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
6
Corrigendum to "The school-led study: Protocol of a cluster-randomised controlled trial of effectiveness to prevent adolescent alcohol misuse, internalising problems, and externalising problems through a personality-targeted intervention delivered by school staff", preventive medicine" [Reports 21 (2021) 101286/PMID: 33384915; PMCID: PMC7772564].《学校主导研究：通过学校工作人员实施的针对个性的干预措施预防青少年酒精滥用、内化问题和外化问题的集群随机对照试验方案》的勘误，《预防医学》[报告21（2021）101286/PMID：33384915；PMCID：PMC7772564]
Prev Med Rep. 2023 Mar 29;34:102196. doi: 10.1016/j.pmedr.2023.102196. eCollection 2023 Aug.
7
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.一项评估巴瑞替尼预防 COVID19 相关血液肿瘤患者呼吸功能不全进展的疗效的 I/II 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4.
8
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性（COVA 研究）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
9
High versus low positive end-expiratory pressure setting in patients receiving veno-venous extracorporeal membrane oxygenation support for severe acute respiratory distress syndrome: study protocol for the multicentre, randomised ExPress SAVER Trial.高与低呼气末正压通气设置在接受体外膜肺氧合支持治疗严重急性呼吸窘迫综合征的患者中的应用：多中心、随机 ExPress SAVER 试验的研究方案。
BMJ Open. 2023 Oct 18;13(10):e072680. doi: 10.1136/bmjopen-2023-072680.
10
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.多臂试验炎症信号抑制剂（MATIS）治疗 COVID-19 轻症或中度肺炎住院患者：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 12;22(1):270. doi: 10.1186/s13063-021-05190-z.
引用本文的文献
1
Conservative or liberal oxygen targets in patients on venoarterial extracorporeal membrane oxygenation.在接受体外膜肺氧合的患者中，保守或宽松的氧目标。
Intensive Care Med. 2024 Sep;50(9):1470-1483. doi: 10.1007/s00134-024-07564-8. Epub 2024 Aug 20.
Zotero 插件